<SEC-DOCUMENT>0001628280-25-050796.txt : 20251110
<SEC-HEADER>0001628280-25-050796.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110081737
ACCESSION NUMBER:		0001628280-25-050796
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		251464502

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adc-20251110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:39c23561-de94-4dcd-a3b8-99e6a05bf719,g:dd2bdc41-f380-4b87-ae5c-05ad230567b0,d:51b60d5215754887a5af8a7e76b1dd27-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>adc-20251110</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-12">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-13">0001771910</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="adc-20251110.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-10</xbrli:startDate><xbrli:endDate>2025-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i51b60d5215754887a5af8a7e76b1dd27_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="border-top:7pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">CURRENT REPORT<br/>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;10, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ADC Therapeutics SA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Switzerland</span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">001-39071</span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification Number)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Biop&#244;le</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Route de la Corniche 3B</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1066 Epalinges</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Switzerland</span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><span><br/></span></div><div style="padding-right:2.75pt"><span><br/></span></div><div style="padding-right:2.75pt"><span><br/></span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">+41 21 653 02 00</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-8">Common Shares, par value CHF 0.08 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-9">ADCT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-10">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. &#167;240.12b-2). Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-11">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:7pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div></div><div id="i51b60d5215754887a5af8a7e76b1dd27_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-14">November&#160;10, 2025</ix:nonNumeric>, ADC Therapeutics SA (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the second quarter ended September&#160;30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits.</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20250930pressrelease.htm">Press Release dated November 10, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.460%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">ADC Therapeutics SA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-15">November&#160;10, 2025</ix:nonNumeric></span></div></td><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jose Carmona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jose Carmona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>adct-20250930pressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i289eb3e1cd584cfc9d82d86342231ef9_1"></div><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">     Exhibit 99.1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">                                                                                    </font><img alt="image_4.jpg" src="image_4.jpg" style="height:93px;margin-bottom:5pt;vertical-align:text-bottom;width:166px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Updated data from Phase 2 IIT of ZYNLONTA&#174; plus rituximab in patients with r&#47;r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Recent financing supports expansion of ZYNLONTA&#174; in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LAUSANNE, Switzerland, Nov. 10, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> -- ADC Therapeutics SA (NYSE&#58; ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2025, and provided operational updates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas,&#8221; said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. &#8220;We look forward to multiple upcoming clinical catalysts expected across LOTIS-7, LOTIS-5, and the ongoing Phase 2 IITs, starting with LOTIS-7 before the end of this year and continuing with data readouts throughout 2026.&#8221;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Third Quarter 2025 Operational Updates &#38; Recent Highlights</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Completed private investment in public equity (PIPE) financing</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company entered into a securities purchase agreement for the sale of its equity securities to certain institutional investors in a $60 million PIPE financing, of which the net proceeds of approximately $57.6 million are anticipated to fund the commercial expansion of ZYNLONTA and strengthen the Company&#8217;s balance sheet.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Updated data from LOTIS-7 expected by the end of the year.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Beyond the initial results reported at European Hematology Association 2025 Congress (EHA2025) and at the International Conference on Malignant Lymphoma (ICML) in June from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI&#174;) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r&#47;r DLBCL), the Company expects to share additional data from the LOTIS-7 trial through a corporate update by the end of the year. Once sufficient data with longer follow-up is available, the Company plans to engage with the U.S. Food and Drug Administration (FDA). In addition, the Company plans to pursue publication and compendia inclusion in the first half of 2027.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">LOTIS-5 topline results anticipated in 1H 2026</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company expects to provide topline data in the first half of 2026 from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab in patients with 2L+ DLBCL once the pre-specified number of progression-free survival (PFS) events is reached and data are available. Assuming positive results, a supplemental Biologics License Application (sBLA) submission to regulatory authorities will follow, with potential confirmatory approval in 2L+ DLBCL as well as publication and compendia inclusion in the first half of 2027.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Updated data from the Phase 2 investigator-initiated trial (IIT) of ZYNLONTA in r&#47;r follicular lymphoma (FL) presented at the 22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> International Workshop on Non-Hodgkin Lymphoma (iwNHL).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Juan Pablo Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presented updated data at iwNHL in September from the Phase 2 IIT evaluating ZYNLONTA in combination with rituximab in r&#47;r FL. Data from the 55 efficacy evaluable patients to date in this trial continue to demonstrate encouraging results with an overall response rate (ORR) of 98.2%, a complete response rate (CR) of 83.6%. After median follow-up of 28th months, median PFS was not reached, and the 12-month PFS was 93.9%. Safety was consistent with the known profile of ZYNLONTA. The trial has been expanded to enroll 100 patients, and the Company plans to assess regulatory and updated compendia pathways as soon as sufficient data are available.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">IND-enabling activities advancing for PSMA-targeting ADC.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> IND-enabling activities are ongoing for the Company's exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC with completion of these activities expected by the end of 2025.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Third Quarter and Year to Date 2025 Financial Results</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Product Revenues&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Net product revenues were $15.8 million for the three months ended September 30, 2025, and $51.2 million for the nine months of 2025 as compared to $18.0 million and $52.9 million for the same periods in 2024. The period-over-period changes were primarily driven by lower sales volume, partially offset by higher sales price and favorability in gross-to-net sales adjustments.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Research and Development (R&#38;D) Expense&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> R&#38;D expense was $26.8 million for the three months ended September 30, 2025, as compared to $32.5 million for the same period in 2024. The decrease in R&#38;D costs for the three-month period was driven by a reduction in spending on discontinued programs and timing and enrollment of our ZYNLONTA clinical trials, partially offset by an increase in IND-enabling activities for our PSMA-targeting ADC. R&#38;D expense was $85.8 million for the nine months ended September 30, 2025, as compared to $82.5 million for the same period in 2024. The increase in R&#38;D costs for the nine-month period was driven by an increase in IND-enabling activities for our PSMA-targeting ADC and timing and enrollment of our ZYNLONTA clinical trials, partially offset by a reduction in spending on discontinued programs.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Selling and Marketing (S&#38;M) Expense&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> S&#38;M expenses were relatively consistent at $10.7 million for the three months ended September 30, 2024, and 2025, respectively. S&#38;M expense was $31.4 million for the nine months ended September 30, 2025, as compared to $32.8 million for the same period in 2024. The period-over-period decrease was primarily due to a reduction in marketing and advertising expenses. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">General &#38; Administrative (G&#38;A) Expense&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> G&#38;A expense was $8.3 million and $27.1 million for the three and nine months ended September 30, 2025, respectively, compared to $10.0 million and $32.3 million for the same periods in 2024. The reductions in G&#38;A expense were primarily due to lower external professional fees.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Restructuring, impairment and other related costs&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> In connection with the strategic reprioritization and restructuring plan announced in June 2025, the Company incurred $0.4 million and $13.5 million in restructuring, impairment and other related costs for the three and nine months ended September 30, 2025, which consisted of $6.2 million in employee severance and related benefit costs, $6.4 million in non-cash impairment of assets and $0.8 million in retirement costs in connection with the close down of the UK facility.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Net Loss&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Net loss for the three months ended September 30, 2025, was $41.0 million, or a net loss of $0.30 per basic and diluted share, as compared to a net loss of $44.0 million, or a net loss of $0.42 per basic and diluted share, for the same period in 2024. The lower net loss for the three-month period was primarily due to lower R&#38;D and G&#38;A expenses. Net loss for </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the nine months ended September 30, 2025, was $136.2 million, or a net loss of $1.14 per basic and diluted share, as compared to a net loss of $127.1 million, or a net loss of $1.35 per basic and diluted share, for the same period in 2024. The higher net loss for the nine-month period was primarily due to the increase in R&#38;D expense, the restructuring, impairment and related costs incurred in connection with the strategic reprioritization and restructuring plan and lower interest income.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Adjusted Net Loss&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Adjusted net loss, which is a non-GAAP financial measure, was $25.5 million, or an adjusted net loss of $0.19 per basic and diluted share for the three months ended September 30, 2025, as compared to adjusted net loss of $29.4 million, or $0.28 per basic and diluted share, for the same period in 2024. Adjusted net loss for the nine months ended September 30, 2025, was $78.2 million, or an adjusted net loss of $0.66 per basic and diluted share, as compared to an adjusted net loss of $84.9 million, or $0.90 per basic and diluted share, for the same period in 2024. The decrease in adjusted net loss for the three-month and nine-month periods was due to lower operating expenses and a higher number of weighted average shares outstanding.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Cash and cash equivalents&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of September 30, 2025, cash and cash equivalents were $234.7 million, compared to $250.9 million as of December 31, 2024. In October, the Company entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million PIPE financing. Giving effect to the estimated net proceeds from the PIPE financing of approximately $57.6 million (after deducting placement agent fees and estimated offering expenses), the Company would have had approximately $292.3 million of cash and cash equivalents as of that date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Conference Call Details</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2025 financial results and provide a company update today at 8&#58;30 a.m. Eastern Time. To access the conference call, please regist</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">er</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> here.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under &#8220;Events &#38; Presentations&#8221; in the Investors section of the ADC Therapeutics website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ir.adctherapeutics.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The archived webcast will be available for 30 days following the call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About ADC Therapeutics</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics (NYSE&#58; ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Headquartered in Lausanne (Biop&#244;le), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;adctherapeutics.com&#47;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and follow us on </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LinkedIn</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA&#174; is a registered trademark of ADC Therapeutics SA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Use of Non-GAAP Financial Measures</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to financial information prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), this document also contains certain non-GAAP financial measures based on management&#8217;s view of performance including&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted total operating expenses</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted net loss</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted net loss per share</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-GAAP measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with GAAP. When preparing these supplemental non-GAAP measures, management typically excludes certain GAAP items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these GAAP items to be normal, recurring cash operating expenses&#59; however, these items may not meet the GAAP definition of unusual or non-recurring items. Since non-GAAP financial measures do not have standardized definitions and meanings, they may differ from the non-GAAP financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other GAAP financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following items are excluded from adjusted total operating expenses&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Shared-Based Compensation Expense&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Restructuring, Impairment and Other Related Costs&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude from our adjusted financial measures costs associated with our execution of certain strategies and initiatives to streamline operations, achieve targeted cost reductions or reprioritize research and development activities. These costs may include employee severance, contract termination costs, facility closing and exit costs, asset impairment charges (which are non-cash) and other costs that we believe do not represent the performance of our business or have a direct correlation to our ongoing or future business operations. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following items are excluded from adjusted net loss and adjusted net loss per share&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Shared-Based Compensation Expense&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Certain Other Items&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude certain other significant items that we believe do not represent the performance of our business, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be&#58; restructuring, impairment and other related costs, changes in the fair value of warrant obligations and the effective interest expense associated with the senior secured term loan facility and the effective interest expense and cumulative catch-up adjustments associated with the deferred royalty obligation under the royalty purchase agreement with HealthCare Royalty Partners.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">See the attached Reconciliation of GAAP Measures to Non-GAAP Measures for explanations of the a</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">mounts excluded and included to arrive at the non-GAAP financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated proceeds to be received in the PIPE, the Company's expected use of proceeds, the expected timing of the closing of the PIPE, the Company's long-term growth potential, the Company's strengthened balance sheet and expected cash runway into 2028, and the Company's expected net product revenues from sales of ZYNLONTA for the third quarter ended September 30, 2025 and its cash and cash equivalents as of September 30, 2025. In some cases you can identify forward-looking statements by terminology such as &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;plan&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;estimate&#34;, &#34;predict&#34;, &#34;potential&#34;, &#34;seem&#34;, &#34;seek&#34;, &#34;future&#34;, &#34;continue&#34;, or &#34;appear&#34; or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to&#58; the success of the Company's strategic restructuring plan&#59; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility&#59; the strengthened balance sheet and expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants&#59; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity&#59; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval&#59; the Company's ability to grow ZYNLONTA&#174; revenue in the United States and potential peak revenue&#59; the ability of our partners to commercialize ZYNLONTA&#174; in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA&#174; in foreign jurisdictions&#59; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA&#59; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and&#47;or compendia strategy and the future opportunity&#59; the timing and outcome of regulatory submissions for the Company's products or product candidates&#59; actions by the FDA or foreign regulatory authorities&#59; projected revenue and expenses&#59; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness&#59; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities&#59; and the uncertainties of international trade policies, including tariffs, sanctions and trade barriers and </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the &#34;Risk Factors&#34; section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i289eb3e1cd584cfc9d82d86342231ef9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except for share and per share data)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.634%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,016&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,894&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues and royalties</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,427</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,464</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,299</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,927</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(851)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,099)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,578)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,803)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,502)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,821)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,532)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,688)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,673)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,388)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,764)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,326)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,002)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,103)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,271)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other related costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(377)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,468)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,396)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,028)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,879)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,145)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss from operations</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30,969)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,564)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(103,580)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(98,218)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,458&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,639&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,392)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,117)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,619)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,292)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,997)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,055)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,215)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,870)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,966)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43,619)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(134,795)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(125,088)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,419)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before equity in net losses of joint venture</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,966)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43,709)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136,214)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(125,575)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in net losses of joint venture</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,544)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,966)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43,969)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136,214)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(127,119)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.35)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,446,534&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,824,877&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,237,877&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,394,355&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i289eb3e1cd584cfc9d82d86342231ef9_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"><tr><td style="width:1.0%"></td><td style="width:63.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,738&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,867&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,316&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,042&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,387&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,928&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">287,149</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">307,390</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,354&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,758</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,980</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,119&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,029&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,440&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,044</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,469</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation, long-term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,093&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loans</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,206&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,632&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, long-term</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,995&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,394&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">527,941</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524,622</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total shareholders&#8217; (deficit) equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(238,183)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(202,642)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and shareholders&#8217; (deficit) equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,758</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,980</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i289eb3e1cd584cfc9d82d86342231ef9_10"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of GAAP Measures to Non-GAAP Measures (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except for share and per share data)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47,396)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54,028)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,632</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(161,879)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(152,145)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,734)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (i)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(807)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,482&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,952&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges (v)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,054&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,054&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges (vi)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted total operating expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45,020)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(51,222)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,202</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(141,929)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(147,193)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,264</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:47.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">in thousands (except for share and per share data)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,966)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43,969)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136,214)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(127,119)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (i)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,482&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,952&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deerfield warrants obligation, change in fair value (income)&#47;expense (ii)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,130)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font id="id791c7a9be6c485ba7a1411afe030cd9_6-0-1-1-299726"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest expense on senior secured term loan facility (iii)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,396&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,401&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation interest expense (iv)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,532&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation cumulative catch-up adjustment income (iv)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges (v)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,054&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges (vi)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,519)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29,382)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78,162)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84,899)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.35)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.19)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.28)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.66)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.90)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,446,534&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,824,877&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,237,877&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,394,355&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i289eb3e1cd584cfc9d82d86342231ef9_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.65pt">Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted and is recognized over the requisite service period less actual forfeitures by a charge to the statement of operations and a corresponding increase in additional paid-in capital within equity. These accounting entries have no cash impact.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.36pt">Change in the fair value of the Deerfield warrant obligation results from the valuation at the end of each accounting period. There are several inputs to these valuations, but those most likely to result in significant changes to the valuations are changes in the value of the underlying instrument (i.e., changes in the price of our common shares) and changes in expected volatility in that price. These accounting entries have no cash impact. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.07pt">Effective interest expense on senior secured term loans relates to the increase in the value of our loans in accordance with the amortized cost method. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.14pt">Deferred royalty obligation interest expense relates to the accretion expense on our deferred royalty obligation pursuant to the royalty purchase agreement with HCR and cumulative catch-up adjustments related to changes in the expected payments to HCR based on a periodic assessment of our underlying revenue projections.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.43pt">Restructuring charges consist primarily of employee severance, contract termination costs and other costs associated to the strategic reprioritization and restructuring plan approved by the Board of Directors on June 11, 2025 (&#34;2025 Restructuring&#34;).</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(vi)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.14pt">Impairment charges consist of write downs of long-lived and prepaid assets associated with the 2025 Restructuring. These accounting entries have no cash impact.</font></div><div style="margin-top:10pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:10pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CONTACT&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:55.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investors and Media</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nicole Riley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ADC Therapeutics</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nicole.Riley&#64;adctherapeutics.com</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">+1 862-926-9040</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>adc-20251110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:39c23561-de94-4dcd-a3b8-99e6a05bf719,g:dd2bdc41-f380-4b87-ae5c-05ad230567b0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adc="http://adctherapeutics.com/20251110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://adctherapeutics.com/20251110">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20251110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20251110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://adctherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adc-20251110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:39c23561-de94-4dcd-a3b8-99e6a05bf719,g:dd2bdc41-f380-4b87-ae5c-05ad230567b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_3aab3aad-3d0d-4767-9b17-06500afccf55_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1c53a02d-6ee1-4d73-b05d-d2394055125d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e02475ed-b8c0-4670-86bf-96780e894c6b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_145ab5bb-16b2-44c6-90ad-9d7b41a98414_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9dd987a4-1846-4004-b956-2a5c87f31e29_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c81c1b2b-f6e2-4d36-9812-b8b86aeb2c78_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a44c7689-0bf6-47aa-9cdc-270495920d5d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_bd32ed0e-96e4-4518-aa2e-9489bc383e36_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3f77e99e-daae-434c-b7e6-390c9913f933_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_812407d0-d33a-40b5-b37d-225bea9a2dff_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_378e9ea5-21a1-4c46-8911-5729443f7782_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b214fe0c-f857-4312-8f64-431566afaed3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e2cc1bb4-9eee-4adc-9716-1f338c9b320c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_45417173-e57b-47ea-b374-d38019f5ef81_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_538ef3b2-911d-4fdd-abd3-13ea626a30f5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2f6a0877-2cf7-4a92-869c-9c4d9e328085_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_28a924a0-5eca-4e38-b41e-9b22a4188ee5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_50cb28a8-c8ec-4429-939f-ccba2a44c514_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_44f13934-9037-4c73-ace0-32ec8185924b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8a2e004f-9de5-45d9-9555-eab22d179c74_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_38e59c29-415b-4c62-832a-dd08d37475d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_40120513-0eb6-42b1-b59b-bf4a42f41a41_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e41635f9-b748-4184-86af-20097102f6a1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adc-20251110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:39c23561-de94-4dcd-a3b8-99e6a05bf719,g:dd2bdc41-f380-4b87-ae5c-05ad230567b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://adctherapeutics.com/role/Cover" xlink:type="simple" xlink:href="adc-20251110.xsd#Cover"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5a9fdc34-a681-4226-b5f6-ddbdbeab046c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_DocumentType_5a9fdc34-a681-4226-b5f6-ddbdbeab046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8eccbb33-2460-4f57-82b5-d6795c760067" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_DocumentPeriodEndDate_8eccbb33-2460-4f57-82b5-d6795c760067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5ce1f944-2748-434d-b44c-62f6244457f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityRegistrantName_5ce1f944-2748-434d-b44c-62f6244457f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4da13811-1274-4428-8ca5-adcb20cd32e9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4da13811-1274-4428-8ca5-adcb20cd32e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e025bfc6-b78d-4f76-b3b0-a61d91874067" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityFileNumber_e025bfc6-b78d-4f76-b3b0-a61d91874067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8e4c152a-98c3-4853-86e9-791a916e4ea7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityAddressAddressLine1_8e4c152a-98c3-4853-86e9-791a916e4ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b3cb3570-56e3-4e03-b4ca-eee0d6128129" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityAddressAddressLine2_b3cb3570-56e3-4e03-b4ca-eee0d6128129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e101a3fd-0c3a-4ad5-92bf-eb09802e9be1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityAddressPostalZipCode_e101a3fd-0c3a-4ad5-92bf-eb09802e9be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7cbf2c10-e668-4138-b014-10d18e5e2eb3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityAddressCityOrTown_7cbf2c10-e668-4138-b014-10d18e5e2eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_a8288e23-e375-46d2-999e-a7cb39b335b5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityAddressCountry_a8288e23-e375-46d2-999e-a7cb39b335b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_9eae05b5-5dd7-44e7-ab82-ce5d5fb40750" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_CountryRegion_9eae05b5-5dd7-44e7-ab82-ce5d5fb40750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d7fa0907-adcb-470d-886a-04d09caa1672" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_CityAreaCode_d7fa0907-adcb-470d-886a-04d09caa1672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f6246845-e4d1-4d02-b129-de786d2b3dda" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_LocalPhoneNumber_f6246845-e4d1-4d02-b129-de786d2b3dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_70d6b4fc-3131-49e5-af4b-c3460fcb0bc7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_WrittenCommunications_70d6b4fc-3131-49e5-af4b-c3460fcb0bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a7c77d43-4a3a-40be-a40a-5a6dd248c311" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_SolicitingMaterial_a7c77d43-4a3a-40be-a40a-5a6dd248c311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_4986f966-0c51-4ada-bd6b-6d225342bea9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_PreCommencementTenderOffer_4986f966-0c51-4ada-bd6b-6d225342bea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e6419fd4-1885-4ac2-874c-dbe2f016371a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e6419fd4-1885-4ac2-874c-dbe2f016371a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_323b65cb-166c-45ee-be13-56cc1f5f10de" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_Security12bTitle_323b65cb-166c-45ee-be13-56cc1f5f10de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1ad6e748-2bc2-4ebe-808c-a3641e0e08e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_TradingSymbol_1ad6e748-2bc2-4ebe-808c-a3641e0e08e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_00badf0b-6309-47b1-bec4-c0e62d692e8a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_SecurityExchangeName_00badf0b-6309-47b1-bec4-c0e62d692e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_466477b5-69a1-4613-9868-44b2a591a992" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityEmergingGrowthCompany_466477b5-69a1-4613-9868-44b2a591a992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b3e8437e-5458-435e-ba56-8e0ccba4ae21" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_AmendmentFlag_b3e8437e-5458-435e-ba56-8e0ccba4ae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_20da9004-2529-4b81-8836-684c0cfa23a2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad70d9c2-2317-49ce-9c73-920910bc3e53" xlink:to="loc_dei_EntityCentralIndexKey_20da9004-2529-4b81-8836-684c0cfa23a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_4.jpg
<TEXT>
begin 644 image_4.jpg
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M> R%\\>=,&!K  !($)>O7B?FHVXF.A0=J7-(1YP<-CEX<@KD1/ASBS6P-0
MQ!Q#ST&4LK,8*N]%Y55'&UOX<XX=L#4  ,00:N@!Q>6BY&*9FPKVQ-O<L#4
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MX4?.6Z6BB66"CC50!6RM!?J[;>>AT_Q!VZ+_&<'6FA")Z6;>BN$W%>SASQ8
MK\#6V4?_;<M<U< IL#60)!+;D7HKAF/S,J 0V#K+-+=UWCIJE>@2?>*V!DZ!
MK8$\T>A>NR^&8U=PH!#8.LN,750BBD2KN*V!4V!K($\DNM=NB^$C=E3PYPF
M#V#K;$)$*%I$JY O$_Q!RP%; U?HW[W^SJ:O127;9'_U1?XD ? !;)TU]%^R
M=>NH51YJX!38&K@B&MUKZ6U2L' +* >VSAK$%J)"M$II11U_T-+ UL M^M^;
M2W[/<,PO \J!K;-#X?:CHC^T2G[1%_Q!NP&V!F[1?^UU3O%?13&;!O/+@')@
MZRR@_Y(M/S5P"FP-/*#_G31%,8OIM[R,/S$ ? -;APVQH.;;EO7Q5P.GP-;
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M8:FL2F?UL,[WAEU<,[9N\YR:_>N;OI:=32-Y9;(8V#H2W+._7M2D)H&M09C
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MV98:YX:M@1*T7G+=LYT9?]  ! !L[86=AT[3%G_00W.6C1Q5.?E7;;/N3&=
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MDEJ<A';$:42M>LM-!7N,YZ2O0JV<D+*V!V!K    7J#]<ODDL'RM$-@:
MT!W8&@   - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8
M&@   - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@
M - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@   - =
MV!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@   - =V!H
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<O[4?V#;E_P?75$V.L?%O6@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADC Therapeutics SA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, par value CHF 0.08 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADCT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001771910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>13</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adc-20251110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="adc-20251110.htm">adc-20251110.htm</File>
    <File>adc-20251110.xsd</File>
    <File>adc-20251110_lab.xml</File>
    <File>adc-20251110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "adc-20251110.htm": {
   "nsprefix": "adc",
   "nsuri": "http://adctherapeutics.com/20251110",
   "dts": {
    "inline": {
     "local": [
      "adc-20251110.htm"
     ]
    },
    "schema": {
     "local": [
      "adc-20251110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adc-20251110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adc-20251110_pre.xml"
     ]
    }
   },
   "keyStandard": 13,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 15
   },
   "report": {
    "R1": {
     "role": "http://adctherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adc-20251110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adc-20251110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-25-050796-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-050796-xbrl.zip
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MOG'KSK[K[.E$YT5;\F:K_J[ LT<OF5#)@3R%ED*" #N//[31Q9!RG-(,PKM
M_>,?%M^C^.O51KK3&6-8AHHI8ZL%FP@#*RD-%8 DB,6H*P5J#P$'4K[[4 ;Q
M0A!6Q;.]2N56A+7I5&[-KM7KVS:59K"V"81<!Q<+0.BE8P4)]^<,(:*#9=4D
M:6G!</+QENKL>W9#J;-XQ@U:-0^W ./TKYG\DW+(&\G:A;"=_*SQ 7VI0Q-'
M9Q"J.?H5(K4@S,1R< K=.$PX!"E=$KFQ]LN2+)I$_7%,PK4KC241Y@^WP"0@
M^;8J+:?AO@Z#:">C$1.JK(I.&/AGB&3!DMM?4OU?TQN<EH]?A]*[O3[JC-(H
MF8 /Z.;%HU O^EL,8'5I04'DM:6%I>+![?YC9;=;9EL9J?Z:;ND]2]*W;[QJ
M=3^BFQGIEC/42S*(5(2B"*-VPF,60FY9>?\J>'.=>AUU4B "DF/Q*EAZ=4CI
MF!!.A5"HZ)RS.&2@+M09TQ!RORN*S@;@,:G813O_82D8**&/!I=,7K/:-<V+
M;;.,_#E'O@1#_E?519Z+ZK4*<CSD."^,J376/,OVW[YI>FYC7Z +&M%TF,2W
M8;[[U?J?LR;TXTAN&]1UDO 10#-3J^$H_YF[I#W$!JH^ [&#H#ZX)HI^PZ(H
M+SY@Q>:)N6X/:?A-EY!QFO(DY4SEJD$R1@&-DFO%M6I4PD!-ZQ,:,!4_$1.(
MJ2UR M*0"1)LE$42QS3)1#1! E"M&$STR'Q $H ,<)'RJ@8^JX5E, ]'.)X4
M;8,D@I>K<4#3%5.9DD [@E+TD<:40U#HQC V,SGTL>W9AMQ=__X2/0;6(Y C
MCH5U3V%N7O7\RID$\:E$,(OS+$ L%I@';$R)I;?UBWIHM73T]DVK 7AS70WT
MB:T'Y7P J_.,H'1NUZ*7089;]6JYEF_L5JA-BAVW@=HG/>15'!LZ+B^F[=1A
M/XE8"%S$EY]AS:@W?U>!M:U3X(P)-,JY6-:>6\66Z\TI<&&/::J^JF.;GB]%
M@^><JA6HSI'H/4?ESSB 3/#2W]-D?>LT"<Q8X1PWWUV3;I58WDZPNYE>3=\7
MJMFN$!GE=]%OXQ7HMT*MZDZXF7[SONOTNRUP92YR&/Q .2"0=-4FN3;M'$_,
M\[T*(OS5MLD>>JKJ(^UM&<B\-C=_X@3F0AWT-$<,PB%J1UC,RDCW*M9O&7L<
M*T)1?S(*DN@U<59LOVN]37T!.(FO0P9/>E-/LL#T0YNM*74_L<.\ YPUKG7B
M>H$V]"(2-B%)A$@#TNH/,:3">RC%'%WA**.H_<L) E_61*DZ0JN:UQ[.>$ S
MVG)!YNO(+*-"BBU]E.7B;_%,[:Q8A^; SQP<4_<(? JM:LSL.)7KP$(&.O^=
M\&^H+Y/PVW0IWRK5!RVG/;E<NS%1"(^B8()"7:L!P/$-70^I/DMPHY#"! +J
M !XJ3'*)+GER+8<***:JN((%(G0 K] 'CDQ>[M16'"&<G1RL&)1HG]@]&ZE3
M;(U]G:4[M5U5(S,XTPLL;].#B,O3*?2I9MBU46<-X7>$W$^::9CS:P7E'S7A
M;4/W=Y,,U_UNEO&,EC>XQ9;VP()6&B9;*NX-P>QH!*@<S"Y.-$;/!-6]0*1Y
M"5%="V(:MYL+#4IR^EW11+U<WR13EA #6]#"Z143, Z,&<>AJEG@,$RR6-<Q
MU 4A@CD1IGA(UB4(E1V\,D&PG\'>IE;P,E.31[TCD=-__VL2&VV0S%]F21-C
MC#ZG$58[CTO76V8D:MJ<V1 <B"3*Y/HA]XHX=VZ\<==FPZL^C>E5GR&?X8]+
M:@6<XF\6'@"Y/HZN\40H<3_L?:!B*A7_+1 2QY"LBVP$9CRY8<OUZ2;H$V81
M74E'R+,=SX:,0621U/O49^"P\@H,N!UT,O5([00\I&JPU]K<DS*UVO&<Q4]]
M+-ZM;GHN?@^M./V-=I2_5ANJGK.?!UK]R]W?!?PC,G#W&#R_.D8 RY=BB#4X
MCB$XA"HXJ,%SH_2F["R*\%RO*OJHGF")H$7T1Z;/92,3K/HTE7/45W+J;70,
MLDNG>UB+)"AD)B7DGXH\A8V&+& 2M5JVJX*2'$*'=L;Y[,J"RD^GVV[*M-CT
MG"C, 5%W>@<2@80HB^WUMSRVP-! C<#!].JO-C-<8%'-_G1]:6X7) 2I911I
M]!"HXTD 2O2V8S UA &+*,G-0&L/(CZX9*J7Z#3B-S=$J7M*17ADU#UO;_.=
M"Z/;4X D46C\&C )$EGP/WB?42I%$<,!B\RK],NQ5%:EZ-D#AGC.&IOG;+VB
M050*!>5[JFLWU'+L/L^&IO(FTMD#!!:"-:M^AHY @3)MN6H;ETHE2X!>0(0P
MEQ7"16I$%@YS<I;=W'-E4DONVZT5[KME.ZX]YZ3UT6SETL2\T8GMX67-606R
M>PNM:U?]VE,Q+_O^B-NPJ\W6@U2SFXY=<5</>9R;&L]5$BW<JSF&]&-EJ&WB
MZP,5(6>I\J\/5,Q]'NY6KWL5#!]15[>YLL'@,5@RI!& 609$^SJFJ5Y #EZ9
M$5!CN?O/21N:?IU"ZL]3.*V*HZ-F#O?LH01YGFL$V,L1(-'AO$"^: 9Z\<V$
MZ/78J^M4']Y<GZ6^W0:]<70.N3#JJL )EJA.)$,"A,T=GAVE5D+RSQYI3*NZ
MJIF0_CP2R9.GW<>K3O_@L,WQPE.><>]^/#V^^-);\56))S>"^<OXILKY1\9X
MCA\W32U6E$=)!F@[Q)DJ:>I4B)L,T*0X L0/#9#  -J#!P#4!PJ1JXFT2\H[
MJ"PPBV&,G@YG<IAP8([<&<R^"-!7;=I-[_:2XZ93U>WJ \U4=>UJ?:,ZZ -=
MWMH.E[EZY:Z\NO]HD&QZD>S)O8(J@CWYQR7<VOV^+K'!#9G;;_IM:*HO*[J_
MG_BO!*>411G]F@#<;&,.!H3OL^)>@4+5H8)-5#KW&2Y@!8DD8F1I>VF;&?U;
MU^98WFM9O^TAHX.Y J6Y\LCOD#.L0?$L5E?._4I]T_N#C[XANMGF9=E\4%-_
MA//H_U!+ P04    "  Q0FI;Z55]E6,"  #_!@  $    &%D8RTR,#(U,3$Q
M,"YX<V3-5%MOVC 4?N=7>'F><X5"4*'26E6:Q"YBK=:WR;%/P&IB9[93Z+^?
M8^(!9:W&GI8GYYSO.Y?/Y_CR:EM7Z F4YE+,@B2, P2"2L;%:A;<W]WB27 U
M'PPNWV'\\&&Y0#>2MC4(@ZX5$ ,,;;A9([,&]%VJ1_Y$T->*F%*J&N.YHUW+
MYEGQU=J@-$Y''N:]:IKE-,U&%PEFD _QD%&&259,<)[#!8E'13E.\O>K*6-I
MP>@PP64VB?&PF(PQ@1'%\8BP-(M'%^,B=D&W>JKI&FJ";&M"3[=Z%JR-::91
MM-ELPDT62K6*TCA.HH=/BV\.&O38BHO'(_2V4)7'9U'G+H@&#R>,_D;;LU5!
MD09:PZD.J:RCKN$D2:RFQ!C%B]; K57F!DK25F86M.)G2RI><F!6]@HZ88\
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MY709P9.@*)4N3?78D7QKW?Q99I6A[:R8SV_S;%G^+*9(AH1#K$"D-3(%8$R
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MWIN!QCOMW9%^ZZQWU_N[4-B<4;.+_#A]M7XE6_XQU=-7_P=02P,$%     @
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MQB2;"MX&4H,W 3!6 !_@4-"NO,)\]U_:Y;M?+MYI <M"=RRPD*0Q#Z\!Q"$
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M,9.,B=V!O"2T2F*J@D#L7)H(Y*G$@#&4U<+:7T=HVD?B] QM*0P/B,<3> )
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M?C6_9<$Q\^DT>!$&0LN5K(E183"G7NJP":D% OI\:@%9]M^8>@&&OD1QMKI
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MP^J6*$Z!W% +8O"F**$Y":(0*56V7<"K_!CW'4QG@6Q)#VEFS4P3>[FC/OP
M:78S//]3N[@T!BW/CT7!-WY?0% J"(\T?(!N)O?*3DU9&_[F\CR?8%,TJA?7
M%*9R,3D +->\;?3I.NJ%99W>1GC7!-5/,8,HF8&>F8#7+H<1M2MM.D#108*S
MB, H+\L:5W7OB%PBF>F)'&*T=MS17$<[6F3Y"_5E)0-+""A=2#TZOAP_A&4F
MHB"%^A?XG:5F&*H%HKJF:@IZY8K",Q&H@G<&0"O(R A/--1DO^9\<P'PVRR(
MP)\0S4):& %TM/', QR.?1SX @OYRN/&>PFK>> W$%;2+A;QWW<L@^>%7#OY
MQ8^FW[\T;?LLX*\6QM4)0LCG$9%7^0YH7@:$/_!;[5\\3OAL-9IS:86U>;%P
M-OT0 ,OR:B.\J4J&8DH@]G8P1!KZ;%-1[TR81\8JBP0C]!NR$<L#TK)#6LIJ
M&;AN8P<E&.[$('LR:\9I.A4Q$6J!HQ\K[!SZ?#]#SK"VG(P7+4L06_N TCMD
M+^]MN!=S3V4YCR/+>:@FRN)$U83J,H6_2*,%P-3$TLQ5T_^TJ_/&*Z75SL3O
M"<4X/^1II+(9[;U((QVH8[%@"Y4A*#]$6U^HOVG,1809([6N&\4>F3VD FF.
MD*P5!5/]'$S1*5FJ<%T6DH7S"72>BX,=P9E X%&0%.C&RX?<DYF']?#,!\6=
MAXO7I^QP$)I4UF4\KAB2=N.#KL?1+#RF+>!2:0@)I@7FXOU/T<,WA[PMYH=K
M3&?==MIEU:N7\L/=^?QP&N'DFN5DF +W5L"=IRX5>+<*7LHZ4YKV,*7_^S*;
MD6%F.LG #2V$K"]FUJ!8O\6)E),H],';+]JCRM$:&.^ISK&NB%Y=RUU?;)O/
MP 'B%3$@YC;@TR;LJYP-+>MZ/'"M$O+DP+I@L9<'*V$]D5M,;P>O"V<SM[4_
MN#;DX/!3P%Q,)L)T98ZQ%3HD3ZS SG&$=57AT03D/!)=%"N33TEQ[3P??P<<
M*C,]9*B-B@\FZ,C&E,_#(=DE_$73+)7]8G*G J**&A.IWKRM5DY !O-]K$TQ
MYDO/$" 68R'E_5B90&%B@$BA50LX4'HR\">^#,GCXE: B\:3CBFA.>2BUMK+
M/?2*"2&ZCW!T"&9\P8V0J*(]XR"SH4@"4SQ:EX5CFYD:N&Q -)*BN$R21,+G
MYZ,M;5&O CJ=3=$I#W .'1H%O+0XZ"8_Y9-$T%#E+B_B8B!*3F18Z .BD6:>
MW?"\03"?#[$2?6WMC9A>CAZ^OO+I.5CEMJH+BA#L(3XJP$X4+(^C$=F8*E[6
MJV#G#,ZT<72+X2M=/DX\"9,\^"X:X8WPI[=X?$3SP01;96&69*BP8X)F^3IZ
M1%N[\A$K=UEH7D0O(>(B=D$6QCA)^2+)^)R%\.2$%CFCU8GH5QF=O.L]%+49
MSF0(4*1(?5X4?U%;C1@D[\>2U4,ZXR0O-Q+X6WYR6_N%NRP3=K^ 7X5)=,J7
M27Y8P-I=0H?A[$Z\6"YXS;:.+[*-2:HRZR0H$7E(,J$GL,WNLQ=7V^\' !QZ
MTN;G"%RA4>&U?B$_YX+&%B5"0E8;[NZ+?FT%DW\42!.FCPQ*N]5%YGUKA%04
MC'?QQ%#RV7U/JQ1TYOTXNC8*L,R7,E7T,EG=A[-%Q6^%JSBB7(44[4AZ*)]0
ML8#DQR6B QI'(%S)"I(:&DP ]ZN<:Q$)/2ZFW%<7>RVR]J02DB3C'@C(^R"3
MS[H2^I*RM=4Y8<.RC!3S]0GG(H=+VEVGD$LNDO,GRFT,\:@XDG BA>9/T!+
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MIJ3H5='KAD&SOFX\H&;L *;I;>ID[>@9%8A9 !8ORH8!?X)1<&J)![[$HT]
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M(V\&_QNGD^#G_P]02P$"% ,4    "  Q0FI;7XMT3+D-  "35@  $
M        @ $     861C+3(P,C4Q,3$P+FAT;5!+ 0(4 Q0    ( #%":EOI
M57V58P(  /\&   0              "  ><-  !A9&,M,C R-3$Q,3 N>'-D
M4$L! A0#%     @ ,4)J6^1-83,Q"@  '%<  !0              ( !>!
M &%D8RTR,#(U,3$Q,%]L86(N>&UL4$L! A0#%     @ ,4)J6U&2D+O'!@
MM3(  !0              ( !VQH  &%D8RTR,#(U,3$Q,%]P<F4N>&UL4$L!
M A0#%     @ ,4)J6QU/L '=.   .P # !T              ( !U"$  &%D
M8W0M,C R-3 Y,S!P<F5S<W)E;&5A<V4N:'1M4$L%!@     %  4 2P$  .Q:
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>adc-20251110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adc-20251110.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-12">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-13">0001771910</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ADC Therapeutics SA</dei:EntityRegistrantName>
    <dei:WrittenCommunications contextRef="c-1" id="f-4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-5">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-7">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-8">Common Shares, par value CHF 0.08 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-9">ADCT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-10">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-11">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-14">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-15">2025-11-10</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
